
On Monday, Bavarian Nordic signed a very important and positive deal with Nuance Pharma, says Senior Equity Analyst at Sydbank Søren Løntoft Hansen. He has kept an eye on Bavarian’s stock following the news, reporting that the Danish company has had a markedly better start than the general market today.
The deal with the Shanghai-based biotech company entails the rights in China and a string of other Asian countries for Bavarian’s RSV vaccine candidate, MVA-BN RSV.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app